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RESEARCH LETTERS

Metabolomic Patterns
in Adolescents
With Mild to Moderate CKD
To the Editor: Metabolomics of patients with chronic
kidney disease (CKD) can provide a unique perspective
on subclinical metabolic perturbations relative to the
glomerular ﬁltration rate (GFR) because the kidneys
have a major role in maintaining metabolic homeostasis.1 Examination of metabolomics in CKD has largely
focused on adults in advanced stages and centered on
risk of mortality.2 However, metabolic alterations in
children and adolescents with mild-moderate CKD
presents a signiﬁcant risk of secondary morbidities
because they are undergoing periods of rapid growth
and development and would otherwise not normally
experience untoward issues with nutrient catabolism.
The goal of this study was to use targeted metabolomics to identify altered biochemical pathways in
adolescents with mild to moderate CKD (stages 2 and
3b) in 2 cohorts matched by age, gender, and CKD
etiology.3 Metabolites and their ratios were selected a
priori due to previously documented alterations in
CKD.4–9
For this investigation, CKD etiology was categorized
as glomerulopathy (G) or nonglomerular urologic
anomalies (NG), the latter of which is deﬁned as
congenital abnormalities of the kidney and urinary
tract and includes the largest proportion of the pediatric CKD population. Therefore, the 2 cohorts (CKD-2
and -3b) had equal numbers with G and NG.
Forty plasma specimens and data, including directly
measured GFR (mGFR, determined by plasma iohexol
clearance)10 were selected from a large heterogeneous
population of children and adolescents in the ongoing,
prospective, observational Chronic Kidney Disease in
Children (CKiD) study in North America.4 By closely
matching the cohorts, an unbiased approach to the
metabolomics of mild to moderate CKD was achieved.
We posited that abnormal metabolic ﬁndings would
be present in early (mild) CKD (stage 2), with some
signiﬁcant differences observed between CKD stages 2
and 3b (moderate).
RESULTS
Two cohorts (CKD-2 and -3b) were deﬁned by their
respective median and interquartile range mGFR that
matched the National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative criteria for stages 2
and 3b.3 The CKD-2 and -3b mGFR medians and
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interquartile ranges were 74.3 (67.4, 82.9) and 32.8
(24.3, 35.5) ml/min per 1.73 m2 (P < 0.001), respectively. Median age was also matched between the cohorts. The racial compositions of both cohorts were
70% White, 5% Native American, and 5% “other,”
whereas CKD-2 and -3b were 20% and 5% African
American, respectively. Carbohydrate, total fat, and
protein intake (grams per day) by food frequency did not
differ appreciably between the cohorts (P ¼ 0.19–0.63).
The cohorts (n ¼ 20/cohort) were compared by stage
for metabolites using a discrete t-test. Subgroups (n ¼
10/subgroup), deﬁned by CKD stage and etiology, were
analyzed using 1-way analysis of variance and post hoc
testing (Table 1).
Five metabolites and ratios were signiﬁcantly different
between the cohorts, comprising a biogenic amine,
phosphatidylcholine; metabolites, tryptophan (Trp),
kynurenine (Kyn), and creatinine (Cr); and an acylcarnitine (P # 0.001). Ratios included tyrosine/creatinine (Tyr/
Cr), ornithine/citrulline (Orn/Cit), Kyn/Trp, proline/Cit
(Pro/Cit), phenylalanine/Trp (Phe/Trp), and symmetric
dimethylarginine/asymmetric dimethylarginine (SDMA/
ADMA) (P # 0.0012) (Figure 1a–j).
Three metabolites and 5 ratios were identiﬁed as
different between the subgroups (P ¼ 0.004–0.02).
Subgroup and cohort results reﬂected metabolite differences, whereas ratio ﬁndings were identical. Distinctions between the subgroups were consistent with
biochemical pathways, catabolic alterations from
declining mGFR, and disease etiology (Supplementary
Material).
DISCUSSION
Methylated arginine derivatives, SDMA and ADMA,
elevated concentrations result from increased protein
catabolism. SDMA increases in early CKD because it is
largely excreted through the kidneys unmetabolized.
Conversely, ADMA has a pronounced rise that is synonymous with advanced CKD decline in the enzyme,
dimethylarginine dimethylaminohydrolase (DDAH 1) and
increased oxidative stress.6, 11–13 Therefore, we expected
and did observe higher concentrations of SDMA and
SDMA/ADMA ratio in CKD-3b and 3b-G, respectively.
Amino acid losses in late-stage kidney disease are
known and anticipated secondary to acidosis, albeit there
is limited literature on mild-moderate CKD.13 Our results
demonstrated some important differences in amino acid
concentrations between the cohorts, whereas macronutrient intake data were not signiﬁcantly different. It is
well-known that there are age-dependent variations in
plasma amino acid concentrations in healthy children
aged 0 to 18 years, and as such emphasize the value of
Kidney International Reports (2019) 4, 720–732
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Table 1. Subject characteristics and signiﬁcant differences in plasma metabolites and metabolite ratios by CKD cohort (median and
interquartile range)
CKD stage 2 (n[20)

CKD stage 3b (n[20)

P

mGFR (ml/min per 1.73 m )

74.3 (67.4, 82.9)

32.8 (24.3, 35.5)

< 0.001a

Age, yr

15.0 (12.7, 15.7)

14.8 (11.7, 16.1)

0.59

Body mass index (BMI) Z

0.95 (-0.07, 1.63)

0.34 (-0.10, 0.82)

0.79

Serum PTH (pg/ml)

33.0 (26.0, 50.2)

60.0 (37.3, 197.0)

0.03a

Urine Pro/Cr ratio

0.34 (0.14, 1.76)

0.63 (0.16, 1.58)

0.56

CKD stage 2

CKD stage 3b

T statistic

P

FDR

[

5.6057

1.98E-06

3.09E-04

4.4398

7.50E-05

5.85E-03

[

4.2039

1.54E-04

7.98E-03

[

3.9549

3.23E-04

1.26E-02

3.5496

1.05E-03

3.27E-02

Variables
2

Metabolites
SDMA

[

PC ae (C32:1)
Kynurenine
Creatinine

[

C4:1
Metabolite ratios
Tyr/Cr

[

5.3733

4.12E-06

2.47E-05

Orn/Cit

[

4.2933

1.17E-04

3.52E-04

[

Kyn/Trp
[

Pro/Cit

[

SDMA/ADMA

4.112

2.02E-04

4.05E-04

3.7856

5.30E-04

7.96E-04

3.5173

1.15E-03

1.38E-03

2

Body mass index (weight in kg/height in meters ) corrected for gender and age. The arrows indicate which metabolites and ratios were higher in CKD Stage 2 or 3b cohort.
ADMA, asymmetric dimethylarginine; Cit, citrulline; CKD, chronic kidney disease; Cr, creatinine; C4:1, butenoylcarnitine (fatty acylcarnitine); FDR, false discovery rate (5% of signiﬁcant
tests will result in false positives); Kyn, kynurenine; mGFR, measured glomerular ﬁltration rate; Orn, ornithine; PCae (C32:1), phosphatidylcholine with acyl-akyl residue; Pro, proline; PTH,
parathyroid hormone; SDMA, symmetric dimethylarginine; Trp, tryptophan; Tyr, tyrosine.
a
Differences between the CKD cohorts were considered to be significant when P < 0.001.

matching age and gender between our CKD cohorts in
this investigation.14
Kyn and Kyn/Trp levels have been associated with
CKD severity and known to be elevated in patients on

chronic hemodialysis.5 Kyn has been suggested to infer
the coexistence of proinﬂammatory processes. Thus,
our observations of increased Kyn and Kyn/Trp in
glomerulopathy (Figure 1a–j) and CKD-3b, respectively,

Figure 1. (a–j) Plasma metabolites and ratios differ signiﬁcantly between chronic kidney disease (CKD) cohorts (stages 2 and 3b; n ¼ 20/group;
false discovery rate <0.05). ADMA, asymmetric dimethylarginine; Cit, citrulline; Cr, creatinine; C4:1, butenoylcarnitine (fatty acylcarnitine);
FDR, false discovery rate (5% of significant tests will result in false positives); Kyn, kynurenine; Orn, ornithine; PC ae (C32:1), phosphatidylcholine
with acyl-akyl residue; Pro, proline; SDMA, symmetric dimethylarginine; Trp, tryptophan; Tyr, tyrosine.
Kidney International Reports (2019) 4, 720–732
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are noteworthy.4 As such, our ﬁndings suggest
upregulated Trp catabolism in glomerulopathy and
moderate CKD.
The higher Tyr/Cr ratio observed in CKD-2 is consistent with an elevated Cr concentration in CKD-3b. In
normal conditions, substantial conversion of Phe to Tyr
occurs in the kidneys, but as GFR declines, conversion to
Tyr is reduced. This explains our observation of attenuated CKD-3b Tyr/Cr levels. This is consistent with
previous ﬁndings in adults and infants with CKD.7,15
Moreover, in advanced CKD, gut microbiota metabolize
Tyr into protein-bound p-Cresol, a phenolic compound
and uremic toxin creating a further decline in Tyr, while
Cr continues to rise.9
Cit, a urea cycle intermediary, was also higher in
CKD 3b-G (mGFR median ¼ 32.8 ml/min per 1.73 m2)
(Supplementary Table S1) and is consistent with previous ﬁndings in patients with a GFR <45 ml/min per
1.73 m2.4 Cit has an important function in advancing
CKD as a hydroxyl radical scavenger and is catabolized
to arginine and then nitric oxide.4 However, as renal
dysfunction worsens and plasma ADMA rises, nitric
oxide synthesis declines.4 Cit also can be directly
converted to Orn, or to arginine by addition of a second
amino group, or regenerated to Orn in the urea cycle.
Moreover, Orn can be enzymatically converted into
proline, accounting for the higher Orn/Cit and Pro/Cit
ratios observed in CKD-2 cohort and subgroups (Supplementary Table S2).
Both PC ae C32:1 and C4:1, a phosphatidylcholine
and fatty acylcarnitine (butenoylcarnitine), respectively, had noticeably lower plasma concentrations in
CKD-3b compared with CKD-2. Our ﬁndings are similar
to another investigation that identiﬁed lower plasma
phosphatidylcholine levels in healthy controls versus
CKD-4.16 So too, acylcarnitines decline in advancing
CKD with relative and absolute carnitine deﬁciencies in
patients with CKD-5 on chronic dialysis.17 In end-stage
disease, tissue carnitine deﬁciency impedes fat beta
oxidation, causing generalized weakness, particularly
following hemo- and peritoneal dialysis, which further
deplete carnitine. The fact that lower acylcarnitine
levels already exist in CKD-3b is of importance for
adolescents who have not reached their full stature and
anthropometric maturity.
There are 2 limitations to this pilot investigation. A
small number of subjects were studied (2 cohorts of
n ¼ 20) matched by age, gender, and mGFR (cohorts of
CKD-2 and -3b). Four smaller subgroups (n ¼ 10)
within the cohorts were matched by etiology and
examined for stage by etiology interaction, thereby
limiting the power for determining signiﬁcant differences. Also, the targeted metabolite panel
722

(Supplementary Figures S1A and B and S2A and B) was
preselected, thereby limiting a complete examination of
some biochemical pathways that were of interest from
our results, including the Trp-Kyn catabolism, which
may have provided additional valuable data.
In summary, mild metabolic derangements exist in
CKD-3b (Supplementary Figure S3A–H). In this study,
we were fortunate to include directly measured GFR
data, which permitted us to better interpret our results
in light of quantiﬁed kidney function rather than by
estimation. Prospective studies are needed to determine
if the metabolic alterations we have observed may
contribute, in part, to growth limitations (stature and
body composition) or whether they have a role in
accelerating CKD progression.
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Performance
of the Automated
Urinalysis in Diagnosis
of Proliferative
Glomerulonephritis
To the Editor: The examination of urine to diagnose
disease is an age-old practice, dating back thousands
of years in primitive forms, and arguably represents
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